ESMO Annals of Oncology
ESMO Annals of Oncology is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at ESMO Annals of Oncology.
ESMO Annals of Oncology is a company.
Key people at ESMO Annals of Oncology.
ESMO Annals of Oncology is not a company but the flagship scientific journal of the European Society for Medical Oncology (ESMO), a non-profit professional society dedicated to advancing cancer care.[1][2][3] Launched in 1989, it publishes peer-reviewed research on medical oncology, surgery, radiotherapy, paediatric oncology, basic research, and comprehensive cancer management, serving oncologists, researchers, and healthcare professionals worldwide with an impact factor of 56.7 and nearly 1 million unique visitors annually from 221 countries.[3][4] As the official journal of both ESMO and the Japanese Society of Medical Oncology (JSMO), it disseminates innovative treatments, precision medicine insights, and clinical guidelines, playing a pivotal role in evidence-based oncology practice.[2][4][5]
Its core mission focuses on fostering innovation to improve patient outcomes through high-quality, multidisciplinary content, including editorials, reviews, original articles, and letters, often tied to major events like the annual ESMO Congress.[1][2][3]
The European Society for Medical Oncology (ESMO) was founded in 1975 in Switzerland by medical oncologists aiming to advance cancer care and foster collaboration among professionals.[1] In its early years, ESMO emphasized education and networking via specialized courses and meetings, expanding internationally in the 1990s and introducing Clinical Practice Guidelines in 1993 to set global treatment standards.[1]
Annals of Oncology emerged in 1989 as ESMO's official journal, marking 35 years in 2024 with a legacy of publishing groundbreaking oncology research.[2][3] Key milestones include coverage of immuno-oncology breakthroughs at the 2014 ESMO Congress (e.g., pembrolizumab for melanoma), precision medicine in 2018, and major advances in immunotherapy at the 2024 Congress, alongside adaptations like virtual events during COVID-19.[1][2]
Annals of Oncology rides the wave of precision oncology, immunotherapy, and AI-driven pathology, amplifying trends like targeted therapies and cell-based treatments highlighted at recent ESMO Congresses.[1][2][3] Its timing aligns with explosive growth in oncology R&D, where global collaboration is essential amid rising cancer incidence and personalized medicine demands—market forces like drug approvals for lung/breast cancer and post-COVID virtual dissemination accelerate its influence.[1][2]
By providing a platform for international research (25,000+ ESMO members from 160+ countries), it shapes ecosystem standards, informs clinical trials, and bridges researchers with practitioners, driving adoption of innovations like Nectin-4 ADCs and CAR T-cell therapies.[1][3]
Annals of Oncology will deepen its focus on personalized medicine, emerging therapies, and AI applications, sustaining its role as a vital resource amid accelerating oncology advancements.[2][3] Trends like immuno-oncology expansions and global data integration will propel its influence, potentially enhancing tools for therapy evaluation and real-world evidence.
As ESMO's cornerstone, it ties back to its foundational goal: connecting experts to push cancer treatment boundaries, offering sustained hope for improved patient outcomes.[1][2]
Key people at ESMO Annals of Oncology.
